Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.

RENEURON- stem cell technology (RENE)     

Tonker - 27 Feb 2006 08:22

Think this one could have the potetial to be really big... Check out the company info and post any thoughts you have... has massive potential

Tonker - 05 Mar 2006 21:00 - 2 of 69

Stem cell tech coulde make this a real winner. S.p is historically low at the mo.... good time to buy... am not sure yet... on wach list

ssanebs - 06 Dec 2006 14:03 - 3 of 69

has everyone missed this one....from 3 to 19

Tonker - 06 Dec 2006 15:53 - 4 of 69

I did not thanks.... no seemed interested in the thread though... when the democrats gained control of the two houses in US I went in..... bought at 7.5p still holding

soul traders - 06 Dec 2006 16:03 - 5 of 69

"no seemed interested in the thread though"

Tonker, my friend, if you want people to read your stuff you have to be prepared to provide a bit more information, at least explaining why you think the company "could be big". You'll probably then have to add in a few updates over the following few days to keep putting the thread in front of people's eyeballs and then people will start to get interested.

There is too much info on these BB's for all of us to read all of it, and there are also far too many people who simply state that a particular share is going to be a whopping success, some of them up to no good.

soul traders - 06 Dec 2006 16:04 - 6 of 69

Also a more eye-catching headline could be useful.

ssanebs - 06 Dec 2006 16:04 - 7 of 69

yes i agree. tonker can you post your info on this one.

Tonker - 06 Dec 2006 16:05 - 8 of 69

point taken

Tonker - 07 Dec 2006 07:43 - 9 of 69

5 director made purchases yesterday, 189300 shares, 0.2% of company

soul traders - 07 Dec 2006 09:18 - 10 of 69

Up again today : RENE Bid: 24p Offer: 25.5p Change: 5

Looks tempting, but I am concerned that the valuation is a long way from being supported by the fundamentals, even at this small market cap. With my one-month lock-in obligation, I'd be worried about getting stuck.

soul traders - 07 Dec 2006 09:19 - 11 of 69

Say, Tonker, you don't think people are buying Reneuron because they think that RENE is the ticker symbol for Renesola ?? ;o)

lanayel - 07 Dec 2006 09:47 - 12 of 69

The director purchases total around 40,000 between all five !!!
It does not justify the share price being marked up as it has done this morning.
As soul traders mentioned above the current valuation is looking a long long way into the future so be careful !!!

Ian

Tonker - 07 Dec 2006 12:21 - 13 of 69

Soul Trader, maybe |o|... I am lovin' it, could be on for a five bagger, my best ever by a long shot....

soul traders - 07 Dec 2006 14:50 - 14 of 69

Holy smoke, Tonker: RENE Bid: 35p Offer: 36p Change: 15.75

Up about 90% today! I think it really hs been mistaken for SOLA !!

TheMaster - 07 Dec 2006 20:00 - 15 of 69

Press report in the Evening Standard tonight (page 32), highest raiser on their chart in the Business section.
Should get more coverage in the morning papers, this bio has huge potential.

Tonker - 08 Dec 2006 08:36 - 16 of 69

The gravy train is slowing down, could go down today

potatohead - 08 Dec 2006 11:48 - 17 of 69

i think this news is pretty major, my reckoning we will get more news than bargained for

HenryFord - 7 Dec'06 - 20:05 - 14498 of 14516

BioMerieux, awarded 54.5m, will focus on the development of new molecular diagnostic platforms to perform high-added-value analyses of infectious diseases and cancers.

http://www.drugresearcher.com/news/ng.asp?n=72476-merieux-alliance-transgene-aii-personalised-medicine-biomerieux

getting back to the RELEVANT RESEARCH

HenryFord - 7 Dec'06 - 20:07 - 14499 of 14516

http://www.investegate.co.uk/Article.aspx?id=200607120700230534G

Cannoncan - 7 Dec'06 - 20:33 - 14500 of 14516 edit

;-)

HenryFord - 7 Dec'06 - 20:44 - 14501 of 14516

You can clearly see the "Personalised Medicine" Potential in the diagnostic side of Eirx. It's on a par commercially with a blockbusting drug down the road.
You can also see that its the Colerectal Cancer Research of Eirx that BioMeriux are clearly after, a collaboration with a $2B sales pa company and reciprocal IP deal is clearly not to be sniffed at.

TheMaster - 08 Dec 2006 11:56 - 18 of 69

Check out the BBC web-site for RENE

http://news.bbc.co.uk/2/hi/health/6207236.stm

Tonker - 08 Dec 2006 20:59 - 19 of 69

.

TheMaster - 11 Dec 2006 08:38 - 20 of 69

This is about to rise up now the MM's have duped the weak holders

hlyeo98 - 11 Dec 2006 12:00 - 21 of 69

Chart.aspx?Provider=EODIntra&Code=RENE&S

TheMaster - 11 Dec 2006 14:02 - 22 of 69

From the other side:

ReNeuron is presenting at the following conferences:

Genesis VI 12 December 2006 London, England


The Leading biotechnology networking conference

The annual Genesis Conference is the London Biotechnology Networks premier event. Now in its sixth year, Genesis has established itself as a must in the biotech calendar.

Building on the success of 2005, the 2nd Annual UK Biotechnology Company Showcase will this year be an integral part of the event held the preceding day, Monday 11th December 2006.

We are delighted to announce that the Society for Medicines Research, founded in 1966 has agreed to hold their December meeting with us, alongside the UK Biotechnology Company Showcase. This will be the first time two such events, one aimed at the scientific and technical aspects of BioPharma R&D, the other at the corporate development and partnering aspects, are delivered in this way. The sessions will be themed and complementary, allowing each delegate the option to listen within their chosen therapeutic field or cross-discipline as the day progresses.

The London Edge Biotechnology Executive Reception being held on the eveing of 11th December is the next step in the London Edge series being spearheaded by the Londoin Stock Exchange.

In response to feedback from delegates, this year we have also created more depth to the program in the two areas requested: Biomedical Innovation and presentations for international companies. The "Biomedical Innovation Showcase" in the afternoon is being led by Dr Vivienne Cox of UK Bioscience Consultants and will showcase numerous near market medical technology opportunities. We have two opportunities to see leading international companies: "All I want for Xmas...." where six companies actively seeking in-licensing opportunities will present their wish list, and the "International Company Showcase" is being organised by WOCP and sponsored by International Business Wales

The emphasis at Genesis is on the cost effective networking opportunity it provides for the 700+ delegates, complementing the larger more costly partnering events. Such a route enables companies of all sizes to participate fully thereby developing the partnering and investment strategy form a position of knowledge.

driver - 11 Dec 2006 14:16 - 23 of 69

Info is on there Web Site.

http://www.reneuron.com/

http://www.londonbiotechnology.co.uk/genesis/

TheMaster - 12 Dec 2006 12:16 - 24 of 69

News out today USA with regard to RENE, set for lift-off

potatohead - 12 Dec 2006 12:18 - 25 of 69

get in ERX NOW,

Luckypicker - 12 Dec'06 - 12:07 - 14953 of 14962


"john"
12/12/2006 11:53
To
XXX

Subject
Re: Shareholder Question





Hi
As CEO as just returned from the US completing statements
J
------------------
Sent with Instant Email from T-Mobile

-----Original Message-----
From: XXXX
Date: Tue, 12 Dec 2006 11:51:22
To:"John K Pool"
Subject: Re: Shareholder Question

Dear John

why no RNS??






Presenting it like this would've helped - nice find though.- I believe this is worthy of RNS

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
ABOUT LY2181308 AND SURVIVIN
LY2181308 targets survivin, a molecule that supports the survival of
cells that would normally die through programmed cell death or apoptosis.
Survivin helps in the abnormal growth of cancer cells, and is abundant in
many types of cancers, including colon, brain, lung, skin and others, but
nearly nonexistent in normal cells and tissues.

------------------------------------------------------------------------------------------------------------
-

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
7 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06

------------------------------------------------------------------------------------------------------------
-
CARLSBAD, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Eli Lilly and
Company (NYSE: LLY) highlighted two antisense oligonucleotide (ASO) drugs
in its "Update to Wall Street on Strategic Priorities and Pipeline
Progress" on Thursday. Advances with both survivin ASO (LY2181308) and
eIF-4E ASO (LY2275796) drugs were singled out among Select Early- to
Mid-Stage Pipeline Developments. Based on promising activity in early
studies, Lilly said that it is initiating Phase 2 trials for survivin ASO
in a broad range of cancers including liver cancer, prostate cancer, acute
myelogenous leukemia, ovarian cancer and non-small cell lung cancer; the
first of these trials is planned to begin this month. Lilly also said that
the Phase 1 development program for eIF-4E ASO is progressing well.
"We are pleased that Lilly includes our collaboration drugs among its
selected strategic priorities," commented C. Frank Bennett, Ph.D., Isis'
Senior Vice President of Research. "These drugs resulted from our
productive collaboration and Lilly's broad investment in antisense
technologies. We continue to work together and hope that additional drugs
will arise from our collective efforts. Lilly's progress with these
anti-cancer drugs emphasizes the broad therapeutic potential of Isis'
platform antisense technologies, and underscores our strategy of working
with partners to expand the scope of our development pipeline.





Kind regards

TheMaster - 12 Dec 2006 13:10 - 26 of 69

Their US partner 'Stem Cells Inc' has released positive treatment update.
With market over there opening 2.00pm GMT expect further gains later.

stephanie m - 04 Jan 2007 20:00 - 27 of 69

Up 12% today. Could be a lot higher shortly

hlyeo98 - 05 Jan 2007 08:34 - 28 of 69

Drop 19% - why is that?

ssanebs - 05 Jan 2007 10:38 - 29 of 69

profit taking

theentsurgeon - 05 Jan 2007 11:55 - 30 of 69

Stem cell technology (hybrid) in negative light this morning on BBC, see http://news.bbc.co.uk/1/hi/health/6230945.stm.
Should not affect ReNeuron though

WINSORSMYTHE - 05 Jan 2007 14:28 - 31 of 69

It is likely that the BBC 'news' is in mode of "there's no such thing as bad news". Those in the know re SCR appreciate the significant benefits and therefore RENE has a great future. That type of news only serves to make more investors aware and hence quid pro quo.

hlyeo98 - 09 Jan 2007 08:38 - 32 of 69

More negative news for RENE...clinical study put on hold by FDA

ReNeuron Group plc
09 January 2007

Regulatory Update

Guildford, UK, 9 January 2007: ReNeuron Group plc (LSE: RENE) today provides an update regarding its recently filed Investigational New Drug (IND) application
to commence a Phase I clinical study for its ReN001 stem cell therapy for
stroke. The US Food and Drug Administration (FDA) has orally confirmed that it
has placed the proposed clinical study on hold. A telephone conference call
with the FDA to discuss the application is expected to take place later this
week, following which the Company will make a further announcement.



Michael Hunt, Chief Executive Officer of ReNeuron, said:



'We are encouraged to be able to engage in an immediate dialogue with the FDA
regarding our IND application, now that the initial review process has taken
place. Given the ground-breaking nature of our ReN001 therapy and the lack of
comparable approaches addressing stroke, it is not surprising that the FDA might
wish to raise questions or make comments at this point in the approval process.
We look forward to a constructive dialogue with the FDA and, in the meantime, we
continue with our ongoing preparations for the initial ReN001 clinical study.'


soul traders - 09 Jan 2007 10:47 - 33 of 69

Buying opp? RENE Bid: 36p Offer: 38.5p Change: -7.25

hlyeo98 - 09 Jan 2007 11:09 - 34 of 69

I think this will go down to 25p.

stephanie m - 24 Jan 2007 19:06 - 35 of 69

HYLEO
Not exactly 25p. At current 46p think they have a bit further to go

Haystack - 02 Apr 2007 12:45 - 36 of 69

It looks more like it is heading for single figures.

Chart.aspx?Provider=EODIntra&Code=RENE&S

hlyeo98 - 02 Apr 2007 17:56 - 37 of 69

It is already 25p today as I predicted...and I certainly agree with Haystack in his case as RENE has no potential viable product in the short to medium term.
IT IS HEADING FOR 15P next stop. SELL!

swseun - 05 Apr 2007 11:43 - 38 of 69

interesting reading from other thread:

smokin_jokin - 4 Apr'07 - 09:55 - 3546 of 3547

End of tax year lots of people dumping stock to get under CGT threshold, they will be buying back in next week again though...these should tick up hopefully. Love to buy more at this price, but now fully invested.

News soon.

water30 - 4 Apr'07 - 10:17 - 3547 of 3547

Was a former holder of RENE a few months back. I have bought back in because I believe it is massively undervalued but most importantly, I like the potential here. Will look to add more if the price drops again.

:-) enjoy

swseun - 05 Apr 2007 11:45 - 39 of 69

More...

TOPINFO - 3 Apr'07 - 15:59 - 3543 of 3547
I wouldnt go that far but its cheap now thats for sure. Remember broker target is 106p at least.!!!

hangon - 04 Jan 2008 15:40 - 40 of 69

It's not even all-or-nothing.
First we have to overcome the US Authorities, just to start the trial
then we have to wait, hope the trials are positive
and that US Authorities don't put it on Hold again!
and then the Trials have to be positive . . . . and PAID for - that's not cheap!
Then we have to wait for Approval, a commercial deal etc.

Of course by the time we're half-way through the sp will be doubled - but that still means many hurdles before we get there........just overcomming the US-Hold appears to be taxing Execs....I wonder why? . . . . This is nearly 1-year on. . . .

If in the meanwhile they need more Dosh - there will be a Placing; so your investment will be diluted, so anything you paid will have cost, maybe 10% more (effectively)....Grr.

hangon - 19 Mar 2008 16:48 - 41 of 69

Widow and Orphan status springs to mind! - no not the patients who are delayed treatment by the FDA ( see RNS and sp fall today - Yikes!),
No, - I mean the remaining family who "might" have been spared widowhood, at least for a few more weeks, months, etc.

Of course FDA has a responsibility towards trial patients - but to delay Trials twice smacks of Nimbyism, but that's just a sly view - if they fall any further, I might buy for the "future" - the present can't get much worse - or can it?

Perhaps we should allow more foreigners into Britain provided they take part in Trials - they wouldn't mind, would they?

Tonker - 20 May 2008 08:10 - 42 of 69

Attention, Attention....

These boys are shifting, look out

oilyrag - 20 May 2008 08:58 - 43 of 69

Nice rise yesterday, how far is it likely to go. Current sp of 13.75 mid is mcap of 21million approx. Was 12million 2 days ago.

Tonker - 20 May 2008 09:17 - 44 of 69

yeah, I have my stop loss set at 13p at the moment..... I think they could be good to 15p maybe, but time will tell.

The Government had passed a new bill unrestricting the use of certain stem cell techniques

porky - 24 Jan 2009 13:18 - 45 of 69

Very surprised that this has not been flagged up in the last few days.
Share price rise has been terrific on the news from America that the FDA has authorised stem cell research to go ahead in human tests, and it has also been ok`d by UK authorities to go ahead with their stroke stem cells in human tests.
They are still talking to the FDA, and if this turns positive then the price at the moment will be extremely cheap.

porky - 24 Jan 2009 13:20 - 46 of 69

Alert serviceSite mapSearchHome
Home News & events NewsNews article
ReNeuron gains UK regulatory approval to start ground-breaking clinical trial with stem cell therapy for stroke . 19/01/09
Guildford, UK, 19 January 2009: ReNeuron Group plc (LSE: RENE.L) today announces that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a first-in-man clinical trial for the treatment of patients who have been left disabled by an ischaemic stroke, the most common form of the condition. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world.

In this ground-breaking Phase I trial, the first of its kind using expanded neural stem cells, stroke patients will be treated with ReNeuron's ReN001 stem cell therapy at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board. The Principal Investigator for the trial is Dr. Keith Muir, Senior Lecturer in Neurology at the University of Glasgow. MHRA approval for the trial has been given subject to provision of data both from an ongoing pre-clinical study and from the long term follow-up of trial participants. Following successful completion of the ethics approval process which is currently underway for the trial, patient recruitment is expected to commence in the second quarter of this year.

The trial is designed primarily to test the safety profile of ReN001 in ischaemic stroke patients at a range of cell doses, but a number of efficacy measures will also be evaluated over the course of the trial. The ReN001 cells will be administered by direct injection into the affected region of the brain in a straightforward surgical procedure. Importantly, the nature of the procedure and the characteristics of the ReN001 cells mean that the patients will not require immunosuppression following treatment, thus eliminating the safety risks typically associated with immunosuppression regimens. Patients in the trial will be monitored for one year, with longer term follow-up procedures in place thereafter.

Dr. Keith Muir said:

"Stem cell treatment offers the potential to repair brain tissue lost as a result of stroke. We are very excited at the opportunity to undertake this, the first clinical trial involving neural stem cell therapy in stroke. At this stage, we are primarily seeking to establish the safety and feasibility of this form of treatment, and if successful, we hope that it will lead on to larger studies looking at the effects of the treatment on patient recovery".


Michael Hunt, Chief Executive Officer of ReNeuron, said:

"This regulatory approval marks the first step in the process of testing the safety and potency of our lead ReN001 stroke therapy at a clinical level. It is the most important milestone in ReNeuron's history thus far and also represents a significant development in the wider field as regards the translation of exciting stem cell science into clinical stage therapies. In many ways, ReNeuron has set the regulatory pathway in the UK for cell therapy trials of this type, and we are delighted to have been given the opportunity to move ReN001 into its clinical phase on home territory in the UK"


Enquiries:

ReNeuron

hangon - 28 Jan 2009 21:03 - 47 of 69

IMHO, A lot of hot air, for this Co has had a far greater Punter Interest ( and sp) quite some while ago. In that event they muffed it, destroying many shareholder beliefs that this was the way forward.
So not everyone believes this is the start of something BIG....rather it's the same old hooey, relaunched in another guise.
Today, the sp shows that 4x as many punters want "out" as are willing to pay "spike prices" - - - Oh deary.

Andy - 04 Mar 2009 20:16 - 48 of 69

New article, Click HERE

hangon - 12 Mar 2009 17:26 - 49 of 69

FUND-Raising at 3p/Share

Oh deary, for retail shareholders - this will mean DILUTION, no wonder the sp has fallen so quickly today!

-and the way I read it most of this 3million is already spoken-for by way of repaying Loans . . . . . can someone else explain otherwise?

Joe Say - 12 Mar 2009 19:47 - 50 of 69

No need to explain hangon - you're a PI, and you've been shafted

Don't worry though - no need to lose any sleep as the institutions and the board have all been looked after.

justyi - 12 Mar 2009 20:41 - 51 of 69

This is a dummy company...bail out and don't invest in it.

Joe Say - 13 Mar 2009 19:46 - 52 of 69

Couldn't agree more - the board, its advisors et al are init for themselves, and themselves only.

What posters on other boards are assuming is that this fund raising will be enough - that in itself is highly debatable, but the board has certainly shown how it would like to spread the rewards if and when they do come - certainly ain't gonna be for the PI

Balerboy - 16 Nov 2010 17:48 - 53 of 69

Maybe one to tuck away in the bottom draw with this news, if the research comes good could be worth a bit.,.

dreamcatcher - 23 Jun 2012 07:36 - 54 of 69

Thursday we'll have annual results from ReNeuron , the stem technology researcher. The firm is not in profit yet, but it has high hopes for its ReN001 stem cell therapy for the treatment of the effects of a stroke. It is currently in clinical development.

dreamcatcher - 23 Jun 2012 07:38 - 55 of 69

Chart.aspx?Provider=EODIntra&Code=RENE&S

dreamcatcher - 14 Aug 2012 21:44 - 56 of 69

Stroke Trial Update
RNS
RNS Number : 9276J
ReNeuron Group plc
14 August 2012










14 August 2012
AIM: RENE



ReNeuron Group plc

("ReNeuron" or the "Company")



ReNeuron receives DSMB clearance to progress to higher dose in stem cell clinical trial in stroke patients



First patient treated in this higher dose cohort



Guildford, UK, 14 August 2012: ReNeuron Group plc (AIM: RENE) today provides an update on progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. In this open label, dose-ranging Phase I safety study, taking place in Scotland, ReNeuron's ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.



The Company is pleased to report that the independent Data Safety Monitoring Board (DSMB) for the clinical trial has recommended that the trial advances to the evaluation of a higher dose of ReN001 in the third of four dose cohorts to be treated in the study. In arriving at this recommendation, the DSMB reviewed safety data from the first two dose cohorts of six patients treated with ReN001. Of these patients, two are through 18 month follow-up, one is through 12 month follow-up, one is through 9 month follow-up, one is through 6 month follow-up and one is through three month follow-up. No cell-related adverse events or adverse immune-related responses have been reported in any of the patients treated to date.



The Company is also pleased to report that the first patient in this third dose cohort of three patients has now been successfully treated with ReN001 and discharged from hospital with no acute safety issues arising.



The primary aim of the PISCES study is to test the safety and tolerability of the treatment in ascending doses of the ReN001 cells, in patients with moderate to severe functional neurological impairments resulting from their stroke. The secondary aim of the study is to evaluate efficacy measures for the design of future clinical trials with ReN001, including imaging measures as well as a number of tests of sensory, motor and cognitive functions.



In June of this year, interim data from the PISCES study from the first five patients treated was presented by the Glasgow clinical team at Glasgow at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Yokohama, Japan. Reductions in neurological impairment and spasticity were observed in all five patients compared with their stable pre-treatment baseline performance and these improvements were sustained in longer term follow-up.



The PISCES study is the world's first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world. The trial is being conducted in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.



As announced recently, the Company expects that, subject to a continuing lack of cell-related adverse events and affirmative Data Safety Monitoring Board advice, the remaining patients in the PISCES study will have been recruited and treated by early 2013, leaving the Company on track to submit an application for a Phase II clinical study with ReN001 by mid-2013. These remaining patients have already been identified and evaluated as potentially eligible for treatment in the PISCES study, subject to further screening and consenting visits.



Michael Hunt, Chief Executive Officer of ReNeuron, said:



"We are delighted that the DSMB have given a favourable recommendation to proceed to the higher and penultimate dose in the PISCES stroke trial. This represents a further important milestone for the study as we make our plans for a subsequent Phase II clinical trial application with ReNeuron's ReN001 cell-based treatment for stroke disability."


magicjoe - 18 Sep 2012 11:06 - 57 of 69

Spot the movers 3.10 / 3.20p not any longer

After plenty of 50K sells at offer 3.20p ( order book ) the last one of 750K got the shares moving

Chart.aspx?Provider=Intra&Code=rene&Size

magicjoe - 28 Sep 2012 13:07 - 58 of 69

15 small-cap stocks to buy now
By MoneyWeek Editor John Stepek / Sep 27, 2012

Tom: I’ll stick with the biotech theme. One of the few British players is ReNeuron (LSE: RENE), which basically drills holes into the heads of people who have had a stroke, and injects stem cells to try to revive the part of the brain that has been damaged. It’s early days, but so far the treatment doesn’t seem to do these people any harm and there is early evidence that it does some good.

The interesting thing is that Reneuron’s experience is consistent with what has been reported from stem cell trials elsewhere, notably in America. Stem cell medicine is definitely something to keep an eye on, and is part of the emerging business of regenerative medicine.

http://www.moneyweek.com/investment-advice/share-tips/roundtable-15-small-cap-stocks-that-will-grow-through-recession-60824

Hiram Abif - 22 Oct 2014 10:17 - 59 of 69

Have made several buys recently; latest today. Still not being reflected on trade either by correct quantity or type of transaction.

Looks like MM are using 'automatic stabilizer' trades to hold SP at their desired level. Lots of interest in Stem-cell research and relatively few stockmarket companies trading in such technology.

Recent Cell transplant on spinal nerve has just enabled a paralised man to walk again. This is a massive step in tissue repair and Cell regeneration.

DYOR

HAb

midknight - 22 Oct 2014 11:39 - 60 of 69

I think this may be worth watching or holding for the long term.
Neil Woodford recently bought more and now holds about
20%. News.

Hiram Abif - 23 Oct 2014 09:22 - 61 of 69

Good program on TV last night of a man who had his windpipe replaced and reconstructed with StemCells (over a synthetic frame). Pioneering surgery using Stemcell reconstruction.

He can now breath through his mouth (rather than a hole in his his throat) and speak words for the first time since his accident.

StemCell therapy is now real time in surgery and tissue repair. Ignore at your peril!

DYOR

HAb

Bullshare - 22 Jan 2015 17:31 - 62 of 69

The Innovators & Investors Forum is organised in partnership with Cenkos Securities and Shares.

The event aims to showcase up to 40 pioneering and imaginative technology-led firms, bringing them together with the investment community. It combines both a company expo and an educational conference where delegates learn about a range of investment opportunities. 
 
The event is supported with an extensive conference program, including keynote speakers and company presentations. There is also an opportunity to engage in discussions with exhibitors at their stands.
 
 
Participating companies 
 
 
Abzenaeg solutionsMedaPhorShares
AirPortr ELECOMercia TechnologiesSQS
AJ Bell YouinvestEscher GroupPlastics CapitalStadium Group
APC Technology GroupFlowgroupProxamaTyraTech
Atlantis ResourcesForbidden TechnologiesReNeuron GroupXLMedia
blur GroupImperial InnovationsRightster 
BradyInstemRosslyn Analytics 
Cenkos SecuritiesKBC Advanced TechnologiesSeaEnergy 
Deltex Medical GroupManx TelecomServicePower 
 
More companies to be announced
 
 
Event timings
  
Registration:from 09:00
Conference:09:45 - 17:30
Exhibition:09:00 - 18:00
 
Date:

Tuesday 3rd February 2015

Venue:

Business Design Centre, London N1, 52 Upper Street, Islington, London, N1 0QH

Attendance is free, but spaces are limited. Register now to secure your place!
Cenkos Securities
Cenkos Securities 

Cenkos Securities is an independent specialist securities firm focused on UK small and mid-cap companies.

They aim to be entrepreneurial, whilst seeking to establish long-term relationships with corporate and institutional clients.

Their directors and partners have on average more than 25 years' experience in the UK securities market. They have pioneered and led some of the most successful and innovative transactions in the UK securities market over the last decades.

AJ Bell Youinvest
AJ Bell Youinvest 

AJ Bell Youinvest is a multi-award winning provider of SIPPs, stocks and shares ISAs, Junior ISAs, Junior SIPPs and share dealing accounts. We offer customers access to a market leading range of investment options, including: shares, funds, ETFs, investment trusts and much more. Our online dealing service starts from just £4.95 and never costs more than £9.95 per deal.

Shares
Shares 

Shares is the leading weekly publication for the serious private investor. Full of forward facing actionable content, industry leading insight plus honest unbiased content; each week covering areas such as Stocks (Large, Mid or Small Cap), Commodities, Bonds, Funds, Forex, Spreadbetting, CFDs, ISAs, ETFs and personal investing.

Abzena (ABZA:AIM)
Abzena (ABZA:AIM) 

Abzena provides a suite of complementary services and technologies to R&D organisations to improve the chances of successful development of therapeutic proteins and antibodies, and it is therefore poised to capitalise on the growth of the biopharmaceutical market. The Group has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its customers.

Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. The Group’s technologies and services are provided through its wholly-owned subsidiaries, PolyTherics and Antitope.

AirPortr
AirPortr 

Portr is everyone’s personal on-demand porter service, placing less stressful luggage free journeys at travelers’ fingertips.

The service enables passengers to have their luggage delivered between London and it’s airports, same-day, whatever size, wherever they are, whenever needed. They are then free to travel around the city more efficiently, making the most of their time, without their burdensome baggage slowing them down, from only £25.

Combining security, transportation, B2B connectivity and consumer mobile accessibility through technology, Portr has achieved the aviation industry ambition of ‘seamless end-to-end passenger journeys’, delivering innovative solutions, helping airlines and airports improve passenger flows and generate ancillary revenue, while enhancing their travel experiences.  

Having launched at London City Airport in 2014, this year will see Portr’s rollout across a number of London airports.

APC Technology Group (APC:AIM)
APC Technology Group (APC:AIM) 

APC Technology Group PLC provides technologies and services intended to help improve organisational sustainability.  These include sustainability consulting, energy reduction, energy generation, water management and project financing. It is also one of the UK’s leading distributors of specialist electronic components.

Since incorporation in 1982, we have developed outstanding relationships with both specialist manufacturers and our customers, who put significant value on our understanding of their individual business challenges and markets, our technical expertise and the high levels of customer service we provide.

Atlantis Resources (ARL:AIM)
Atlantis Resources (ARL:AIM) 

For more than a decade, Atlantis has been actively involved in the commercialisation of tidal power technology and the development of tidal power projects around the world. Atlantis is striving to become the world’s leading developer of commercial scale tidal power projects and the technologies required to economically deliver tidal current power to the grid for sale and dispatch. Atlantis owns patented technologies covering power generation, turbine deployment and turbine operation and control. The combination of our technology and our track record in successful project origination and development, has created what we believe to be a uniquely commercial force in the marine power industry, able to develop and manage commercial-scale, marine power renewable energy projects globally.

blur Group (BLUR:AIM)
blur Group (BLUR:AIM) 

The way businesses buy and sell services is being revolutionized. blur has torn up the old play book and replaced it with a new one where projects for talented, capable suppliers are won based on merit. We have nearly 50,000 service providers keen to impress you and successfully deliver your project - typically saving you 25%. Businesses like Amazon, Regus, Caterpillar and Argos have changed the way they buy and sell services. They find it easy, fast, fair, with better choice and guaranteed quality. You buy everything else online, why not business services?

Brady (BRY:AIM)
Brady (BRY:AIM) 

Brady Plc is the largest European-headquartered provider of trading and risk management software to the global commodity, energy and recycling markets. Following our listing on AIM, Brady has achieved 50% compound annual growth in revenues over the past five years. It has entered new markets, developed new software solutions, and added global industry leaders as clients. Our growth has resulted from our strategy of combining organic growth with acquisitions, supported by Cenkos, our nomad and broker. Brady is the only UK stock exchange listed company active in the intersection of technology and commodities. We are ranked number one globally in metals, and US recycling, and are the energy Trading and risk Management solution provider with the most energy installations in Europe.

Deltex Medical Group (DEMG:AIM)
Deltex Medical Group (DEMG:AIM) 
Deltex Medical manufactures and markets the CardioQ-ODMÔ system. CardioQ-ODM changes the way doctors care for surgical patients allowing them to recover faster and leave hospital sooner and in better health than they otherwise would do. The performance of the system has been validated through independently conducted, randomised controlled clinical trials and is being translated into routine clinical practice in leading hospitals around the world.
eg solutions (EGS:AIM)
eg solutions (EGS:AIM) 

eg solutions is a back office workforce optimisation software company. eg pioneered this new market space and developed the most complete, purpose built workforce optimisation software for back offices – the only solution that manages work, people and end-to-end processes wherever they are undertaken, anywhere in the world.

Our software is used by leading UK, international and global companies in multiple industry sectors.

Using our forecasting, scheduling, real-time work management and operational analytics capabilities we deliver measureable improvements in service, quality, productivity and regulatory compliance. When supported by our implementation and training services we guarantee return on investment.

ELECO (ELCO:AIM)
ELECO (ELCO:AIM) 

Eleco Plc is an AIM-listed software company with interests based principally in Sweden, Germany and the UK. Eleco develops software tools for the architectural, engineering and construction industries. Eleco is committed to promoting a more sustainable built environment by providing software and services that integrate the construction project delivery process from design through to delivery.

Escher Group (ESCH:AIM)
Escher Group (ESCH:AIM) 

Escher Group Holdings plc is the world leading developer and provider of point of service software for use in the postal industry worldwide. Its core Riposte® software serves 35 national postal services across the world including the United States, Germany, Malaysia, South Africa and Saudi Arabia. The software enables post offices to expand upon their traditional offering, providing new revenue streams, reducing costs and increasing efficiency. The Group has also invested in new products such as Riposte TrEx which is designed to provide a national digital infrastructure linking governments, businesses and citizens via a secure platform. Escher has offices in Dublin, Boston, Singapore, Washington, London and Johannesburg. The Group had an initial public offering in 2011 and is listed on the London Alternative Investment Market (AIM).

Flowgroup (FLOW:AIM)
Flowgroup (FLOW:AIM) 

Flowgroup's patented technology platform will help it dominate the global heating market and the emerging connected home space.

Flowgroup's product range launches with the world's first affordable electricity-generating boiler. This boiler generates low cost, low carbon electricity as it uses gas to heat a home.  It reduces customer electricity bills by 50% and household carbon emissions by up to 20%.  It's designed to become the leading domestic heating technology worldwide with a volume production price close to a standard boiler.

And there's even more to this game-changing boiler.  Couple its generation capability with internet connectivity and an intelligent thermostat and you have the beating heart of the smart, connected home - and a company with global prospects in the most exciting market around.

Forbidden Technologies (FBT:AIM)
Forbidden Technologies (FBT:AIM) 
Forbidden Technologies Plc launched its Forscene cloud video platform in 2004. Used by some of the largest global media players, Forscene is a world leader, having handled 4,000,000 hours of professionally shot source video.
 
During 2013, monthly usage of Forscene rose to over 100 UK TV series. Forbidden capitalised on its successful contract with Google / YouTube by engaging key partners in sports.
 
Gross margins remain in the 85% region.With around 30,000 accounts for its mobile video editing app, Forbidden is positioning to profit from the explosive growth in internet video and mobile devices.
 
In 2013, Forbidden raised over £8m in cash. Forbidden is using this to invest for growth, particularly in the US, where its presence is already being felt.
Imperial Innovations (IVO:AIM)
Imperial Innovations (IVO:AIM) 

Imperial Innovations builds and invests in technology and healthcare companies based on the most promising technologies from our brightest scientists. It is connected with four of the world’s top research universities (Imperial, Cambridge, Oxford and UCL) which between them generate research income of £1.4 billion p.a. A significant technology investor with a portfolio of over 90 companies, Imperial Innovations has invested more than £176.0 million across its portfolio since 2006, and its companies have raised collectively investment of more than £822 million. Innovations invest in the most promising opportunities from whichever technology sector they arise and has built particular expertise in the key sectors of: Therapeutics, Medtech and devices, engineering and materials, and ICT.

Instem (INS.L:AIM)
Instem (INS.L:AIM) 

Instem is a leading provider of IT applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation stage.

Instem’s Early Development Applications (EDA’s) are used in evaluation studies to:

- collect, analyse and report complex scientific data;- comply with regulatory reporting requirements;- improve quality, consistency and efficiency of information reporting; and- reduce the time of critical path R&D activities.

Instem’s solutions are supplied to an international blue chip customer base including AstraZeneca, GlaxoSmithKline and Charles River Laboratories.

KBC Advanced Technologies (KBC:AIM)
KBC Advanced Technologies (KBC:AIM) 
KBC Advanced Technologies plc (KBC.L) is a leading independent consultancy and software company dedicated to the design, operation and management of hydrocarbon processing facilities
worldwide, by empowering our clients with advice and technology to deliver enduring excellence in safety, profitability and environmental performance.
 
Our clients include owners, operators and investors in Oil, Gas, Refining, Petrochemical and relevant Support industries and the technologies at the heart of their operations in Upstream Production and Processing; Mid-stream Gas Handling and Transport; Downstream Refinery Processing, Petrochemicals and supporting Logistics, Financing & Planning. KBC’s client base includes a significant number of national oil companies (NOCs), major international oil companies (IOCs) and independent refiners.
 
KBC was founded in the United Kingdom in 1979 and listed on the London Stock Exchange in 1997. We have 300 staff based in offices across North America, Europe, Middle East, Former Soviet Union and Asia.
Manx Telecom (MANX:AIM)
Manx Telecom (MANX:AIM) 

Manx Telecom is the leading communication solutions provider on the Isle of Man. The Group offers a wide range of fixed line, broadband, mobile and data centre services to businesses, consumers and the public sector on the Isle of Man and provides a growing portfolio of innovative solutions to offshore customers through its Global Solutions division, including Strongest Signal Mobile roaming and Mobile Virtual Network Enabler Services (MVNE). It listed on the AIM section of the London Stock Exchange in February 2014, generated 2013 revenue of £76.0m, +5.0% yoy, and adjusted EBITDA of £27.5m, +11.5% yoy and intends to pay a full year 2014 dividend equivalent to a 7% yield on the IPO price of 142p per share.

MedaPhor (MED:AIM)
MedaPhor (MED:AIM) 

MedaPhor is a global provider of advanced ultrasound education and training for medical professionals. Based in Cardiff in the UK and San Diego in the USA, our aim is simple – to build a world class ultrasound training company that has educational excellence as its core guiding principle.

That core principle is as important now as on the day we started. With products ranging from the very latest in advanced virtual-reality simulation training to hands-on postgraduate courses, we are committed to becoming the world’s leading ultrasound simulation company.

Mercia Technologies (MERC:AIM)
Mercia Technologies (MERC:AIM) 

As an investment business providing funding, hands-on support and accommodation, Mercia's strategy is to provide seed, early stage and development capital from its third party funds under management (via its wholly owned subsidiary Mercia Fund Management) and, at a later stage, provide follow-on capital from its own resources to scale its emerging stars with the goal of realising value for shareholders through an exit over time. Operating nationally with a focus on the Midlands and the North, which have been historically underserved, Mercia has access to enviable sources of deal flow opportunities including partnerships held with nine universities in the region.

Plastics Capital (PLA:AIM)
Plastics Capital (PLA:AIM) 

Plastics Capital is a specialist plastics products manufacturer focused on proprietary products for niche markets. The Group has five factories in the UK, two in China, one in Thailand and sales offices in the USA, Japan, India and China. Plastics Capital was listed on the AIM market in December 2007. 

Currently approximately 40 per cent of sales are exported to over 80 countries worldwide and production is concentrated in the UK where significant engineering know-how and automation underpins the Group’s competitiveness. 

The Group’s corporate strategy is to build shareholder value by continuing to grow its key businesses organically and through value enhancing acquisitions

Proxama (PROX:AIM)
Proxama (PROX:AIM) 

Proxama is a global platform provider of proximity marketing, loyalty and contactless payment solutions on mobile. We provide proximity commerce solutions to financial institutions, media owners, retailers and brands.

Our two technology platforms, TapPoint® and CardGateway®, sit at the heart of our business. TapPoint® delivers proximity engagement and loyalty solutions for retailers, media owners and brands by utilising technologies such as NFC, Bluetooth LE (beacons), geo-fencing and QR codes. CardGateway® is our mobile contactless (NFC) payment platform that enables banks to transition their card portfolio onto mobile, for mobile contactless payments. 

ReNeuron Group (RENE:AIM)
ReNeuron Group (RENE:AIM) 

We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

We have used our unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional drug treatments. Our lead stem cell therapeutic candidate is a therapy for the treatment of patients left disabled by a stroke. Our second application for the CTX cells is for the treatment of critical limb ischaemia. Both treatments are currently in clinical development. Our hRPC stem cell candidate is for the treatment of retinitis pigmentosa, a blindness-causing desease of the retina. This treatment is in late pre-clinical development.

Rightster (RSTR:AIM)
Rightster (RSTR:AIM) 

Rightster is a global b2b video network for distribution, content-sourcing, audience engagement and monetisation. Rightster’s software and services make it simple for sports, fashion, news, entertainment and viral rights holders to maximise the value of their video whether on a licenced, ad-funded, direct to consumer or paid placement basis. Rightster provides an “upload once – commercialise everywhere” solution that extends the reach of live and on-demand video content to web, mobile and connected audiences via clients’ own sites, social channels, portals, platforms, newspapers, magazines and specialist blogs. Thousands of syndication partners are already preconnected, and Rightster’s Multi channel network (MCN) on YouTube consists of 450 channels, regularly featuring in the comScore top partner rankings. Founded by Charlie Muirhead in May 2011, Rightster has since grown to approximately 200 employees across 11 offices in 10 countries.

Rosslyn Analytics (RDT:AIM)
Rosslyn Analytics (RDT:AIM) 

At Rosslyn Analytics, we’re building intelligent businesses.  How?  By enabling our clients to prepare, manage and serve data to their business users.  But, not just any data.  We’re talking smart, enriched, analytics ready data.  With analytics ready data, decisions accelerate.  Teams collaborate.  People innovate.  Businesses captivate.

We’re focused solely on the complex business of data.  And, as business intelligence and analytics make the steady transition to the cloud, we’re taking an evolutionary rather than revolutionary approach.  An approach that bridges the all-important gap between business and data.  Which means data privacy, security and governance is assured. - See more at: http://www.rosslynanalytics.com/company/#sthash.6eCpkQzv.dpuf

SeaEnergy (SEA:AIM)
SeaEnergy (SEA:AIM) 

SeaEnergy PLC (SEA.L) is an innovation-led offshore energy services business.  Since 2012, its focussed strategy has delivered significantly increased turnover, expanded its global reach and is moving towards profitability, in line with expectations.  It comprises:

R2S’s Visual Asset Management, which provides a unique, intuitive and engaging front end for major upstream oil clients’ maintenance management information.  R2S is active in the UK, Gulf of Mexico, Canada and rapidly growing internationally. SeaEnergy’s consultancy focusses on strategic consulting in asset integrity management, management of change and organisational development. Max and Co, our complementary corporate design and communication specialists, combine branding, graphics, 3D animation and web solutions to support clients in communicating complexity.​ SeaEnergy has developed designs and operational concepts for offshore wind farm support vessels which offer significantly improved wind farm economics.  Our ship management team is now managing three vessels and is addressing growth opportunities.
ServicePower (SVR:AIM)
ServicePower (SVR:AIM) 

ServicePower provides connected field services solutions that bring together the customer and the dispatch centre, technician, claims and warranty processes, parts, the contracted workforce, assets, mobility, business intelligence, and social collaboration. ServicePower connects all aspects of the field service value chain through the use of innovative technology that accelerates business efficiency gains and customer satisfaction while reducing costs. ServicePower is uniquely positioned to offer connected field services solutions on one underlying and consistent platform.

SQS (SQS:AIM)
SQS (SQS:AIM) 

The SQS Group (SQS) is the world’s leading specialist in software quality. SQS’ position and expertise as the market leader are the result of over 30 years of successful consultancy. The company’s competitive edge stems mainly from its PractiQ methodology, which is based on many years of project experience and specialist knowledge across a wide range of industries. With over 7,000 completed projects, SQS has a strong customer base, including half of the DAX-30, almost a third of the STOXX-50 and 20 FTSE-100 companies. Our customers include Allianz, Beazley, BP, Centrica, Commerzbank, Daimler, Deutsche Post, Generali, JP Morgan, Meteor, Reuters, UBS and Volkswagen.  

Stadium Group (SDM:AIM)
Stadium Group (SDM:AIM) 

Established over a century ago and headquartered in the UK, Stadium Group plc is an AIM listed, leading electronic technologies group with a turnover of circa £50 million and 800 employees.  Its diverse product portfolio includes power supplies, intelligent interface and displays (Human Machine Interface), M2M (Man-to-Machine) Wireless Connectivity solutions supporting the Internet of Things expansion and integrated electronic manufacturing services (iEMS), which it provides to a broad range of OEMs in the professional electronics market.

Stadium’s products are used in a wide variety of industries including industrial, medical, communications, green technology, automotive, marine, aviation, security and lighting.  It presently operates four manufacturing sites in the UK (Hartlepool, Warrington, Diss and Southampton) a low cost manufacturing operation in China (Dongguan), UK and Asia R&D Centres and commercial offices in the UK, Hong Kong and Australia.

 

TyraTech (TYR:AIM)
TyraTech (TYR:AIM) 

TyraTech, Inc. was established in 2004 to utilize its novel technology to fill the unmet and increasing global demand for effective, safe, and natural pesticide technologies for human and animal health.

TyraTech's products incorporate a unique blend of potent natural active ingredients and are available in a number of markets including consumer, commercial, professional pest control, agriculture, human and animal health, vector control and livestock markets.

TyraTech, Inc. made its Initial Public Offering in June 2007 on the AIM section of the London Stock Exchange, where it trades under two separate common stock share listings (TYR and TYRU). Since going public, TyraTech has established partnerships with market leaders in areas such as human health as well as consumer and commercial pest control operators.

XLMedia (XLM:AIM)
XLMedia (XLM:AIM) 

XLMedia is one of the largest independent online traffic providers to the gambling industry, delivering digital performance marketing services to over 120 operators. It attracts paying users from different online channels and directs them to online gambling operators, typically in return for a revenue share. XLMedia has a scalable platform and clear strategy to support significant growth in both new and existing markets.  With a track record of successful acquisitions it is also well positioned to act as an industry consolidator. In addition, XLMedia has a stated policy of returning at least 50% of retained earnings each year as dividends.

London Stock Exchange
London Stock Exchange 

London Stock Exchange is the world's most international exchange. Nearly 2,500 companies from more than 90 countries are quoted across its markets, with a combined value of £4.4 trillion.

London Stock Exchange's markets include the Main Market - London's flagship venue for equity, debt and exchange traded products, offering businesses access to Europe's most liquid pool of capital - and AIM - the world's leading market for small and growing companies. Since its launch in 1995 AIM has helped 3,500 companies raise £87 billion.

Trading participants access London Stock Exchange markets via a range of secure, low latency interfaces, including the Order book for Retail Bonds (ORB), which since its launch in 2010 has allowed private investors to trade bonds in small denominations, and has helped companies raise over £4 billion.

London Stock Exchange also offers a range of real-time and reference data services, facilitating the trading and reporting of over £1 trillion of securities by 400 members annually.

London Stock Exchange is part of London Stock Exchange Group, which incorporates a range of pan-European trading, technology, post-trade and index businesses.

Miton Group (MGR:AIM)
Miton Group (MGR:AIM) 
Sponsored by:
Cenkos Securities
Shares
AJ Bell Youinvest

js8106455 - 04 Feb 2015 14:47 - 63 of 69

Reneuron - Innovators & Investors Forum

Click here

Bullshare - 11 Jan 2016 16:52 - 64 of 69


MEET THE TECH SUPERSTARS OF TOMORROW


A 12-month share price performance of the companies that presented at the Innovators & Investors Forum last year included:

Elecosoft +42%
Idox +22%
Instem +34%
KBC Advanced +45%
XL Media +41%

The Innovators & Investors Forum, organised in partnership with Cenkos Securities and SHARES, is in its 4th year and is the UK's only technology investment show.

REGISTER NOW

Thousands of investors have attended our previous shows, attendees will also benefit from:

Learning from industry experts and influencers about the markets, the technology sector and individual companies
Find out from fund managers how they view the future in 2016
Meet the directors of up to 30 listed technology focused companies
Listen to our expert team of SHARES journalists

The event is supported with an extensive conference program
Keynote Speakers:

Daniel Coatsworth, Editor - Shares
Mark Dunne, Growth Companies Reporter - SHARES
Steven Frazer, Online Editor - SHARES
Russ Mould, Investment Director - AJ Bell
Richard Penny, Senior Fund Manager - Legal & General UK Alpha Trust
Simon Strong, Head of Research, Growth Companies - Cenkos Securities
Gervais Williams, MD - Miton Group

Further speakers to be announced soon.

Meet the teams and talk directly to CEOs and Directors from:


Abzena
Advanced Oncotherapy
ANGLE
Brady
Cyan
Eckoh
eg solutions
Flowgroup
Harriman House
Ilika
Instem
Kromek
Lombard Risk
Mercia Technologies 
Mirada
Plastics Capital
Quantum Pharma
ReNeuron
Rosslyn Data Technologies
Selftrade
SHARES
Strat Aero
TP Group
TyraTech
XLMedia


Further companies to be announced soon.




Date: 2nd February 2016

Venue: Business Design Centre, London



Event timings

Registration: from 09:00
Conference: 09:45 - 17:00
Exhibition: 09:00 - 18:00



REGISTER NOW

Bullshare - 20 Jan 2016 12:46 - 65 of 69

Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only.

Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutions
Who Should Attend?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Thursday 25th February 2016

Venue:

Radisson Blu Hotel Edinburgh, 80 High Street, The Royal Mile, Edinburgh, EH11TH

Event Timings:
17.45 
Registration and coffee
18.10 
Presentations
• Phil Reason, CEO - Instem (INS)
• Michael Hunt, CFO - ReNeuron Group (RENE)
• Mark Beveridge, FD - Safestay (SSTY)
• Philip Houghton, CEO - Safestay (SSTY)
• Richard Gray, CEO - Scotgold Resources (SGZ)
• Dr. Satu Vainikka, CEO - Valirx (VAL)
20.45 
Drinks reception and canapés
21.45 
Close
Attendance is free, but spaces are limited. Register now to secure your place!
Instem (INS)
Instem (INS) 

Instem is a robust and profitable provider of IT applications and technology enabled services to life sciences R&D.  Instem helps clients to bring life enhancing products to market faster, with the potential for significant return on their investment.

Instem’s solutions are essential to over 400 clients worldwide in areas such as:

· Collection, analysis and reporting of complex scientific data· Compliance with regulatory submission requirements, including the FDA-mandated SEND initiative· Improving quality, consistency and efficiency of critical R&D processes and corresponding information             reporting· Generating new scientific insights through identification, extraction and analysis of actionable information

Instem anticipates continued organic and acquisitive growth in a buoyant life sciences industry.

ReNeuron Group (RENE)
ReNeuron Group (RENE) 

ReNeuron is a leading, clinical-stage cell therapy development business.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. 

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.

Safestay (SSTY)
Safestay (SSTY) 

Safestay PLC is the owner operator of a branded contemporary “boutique” hostel group. The first Hostel in the Elephant and Castle, London was opened in June 2012.The Safestay Business operates a new brand of contemporary hostel, designed to appeal to a broad range of guests. Known as a “boutique hostel” within the travel industry, it is aimed at providing safe, stylish accommodation which offers a more attractive alternative to both traditional hostels and budget hotel accommodation.

Scotgold Resources (SGZ)
Scotgold Resources (SGZ) 

Aus­tralian Secu­ri­ties Exchange listed Scot­gold Resources Lim­ited (ASX:SGZ) was estab­lished in 2007 and listed on the ASX in Jan­u­ary 2008. The company’s shares were admit­ted to trad­ing on the AIM mar­ket of the Lon­don Stock Exchange (AIM:SGZ) in Feb­ru­ary 2010. The Company’s prin­ci­pal objec­tive, since 2008, has been the advance­ment of the Conon­ish Gold and Sil­ver Project in Scotland’s Grampian High­lands to a pro­duc­tion deci­sion and explo­ration of the highly prospec­tive ten­e­ments com­pris­ing the Grampian Gold Project with the view of iden­ti­fy­ing fur­ther project opportunities.

Valirx (VAL)
Valirx (VAL) 

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.

Sponsored by:
Alliance Trust Savings

Bullshare - 14 Oct 2016 10:58 - 66 of 69

Shares Investor Evenings showcase presentations from leading companies bringing them together in one room.

 - Directors present their latest plans regarding development and growth

 - An opportunity to talk directly to the companies and personally put forward your questions

 - The chance to network with other attendees over drinks and canapés - private investors, wealth managers, fund managers and financial institutions

Who Should Attend?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Thursday 27th October 2016

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:
18.00 
Registration and coffee
18.30 
Presentations
• Paul Atherley, MD - Berkeley Energia (BKY)
• Michael Hunt, CFO - ReNeuron Group (RENE)
• Dr Wolfgang Rencken, CEO - Sphere Medical (SPHR)
+ More to be announced
20.30 
Drinks reception and canapés
21.30 
Close
Attendance is free, but spaces are limited. Register now to secure your place!
Berkeley Energia (BKY)
Berkeley Energia (BKY) 

Berkeley Energia Limited (BKY AIM/ASX) is a high impact, clean energy company focussed on bringing its wholly owned Salamanca project into production, commencing initial development in mid-2016.

The world class uranium project is being developed in an historic mining area in western Spain, about three hours west of Madrid. Following recent ministerial approval, the Company has now received all the European Union and National level approvals required for the initial development.

The project will generate measurable social and environmental benefits in the form jobs and skills training in a depressed rural community. It will also make a significant contribution to the security of supply of Europe’s zero carbon energy needs, where Euratom recently rated “lack of investment in new mines” as the number one risk facing European utilities.”

ReNeuron Group (RENE)
ReNeuron Group (RENE) 

ReNeuron is a leading, clinical-stage cell therapy development business.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. 

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.

Sphere Medical (SPHR)
Sphere Medical (SPHR) 

Sphere Medical is a dynamic and growing company specialising in the development of innovative medical monitoring and diagnostic equipment. Their products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs.

Sponsored by:
AJ Bell Youinvest
Shares

hangon - 17 Nov 2016 14:23 - 67 of 69

Did no-one visit this Show...? No opinions, guesses, etc?

The snag with such shows is it has to be companies that haven't got anything better to do - Er, IMHO. otherwise they'd be doing it !
- Shows take Execs away from the daily grind and give them a boost of importance in a warmly reactive audience.
They may have a good tory to tell, but look at their Mkt Cap from previous years - and how is that compared with the Market ( & Sector) in general. We all know that "Rising Tides..." -so these companies need to demonstrate they are getting better, more profitable and gaining more customers even in the teeth of opposition from established competitors - that is the price-point to invest..... where the bad ones have slipped-up and only the good survive. ( Yet the Market hasn't understood this, otherwise you are paying too much! ).
If there is a Dividend..... that's when Punters can judge the value of the investment, since everything else is a Punt, mainly on Execs not blowing the cash-raised on silly things, which lose money.

What were your feelings on going round this Show....
Were they the "Same Faces" as last year ( Listings say they are )..... any look to be a "Turnaround"....?
.

Bullshare - 01 Feb 2017 12:04 - 68 of 69

 
We would like to invite you to our exclusive Shares Investor Evening in Edinburgh on Wednesday 15th Feruary 2017. Following the success of our regular investor events in London and our event last October in Edinburgh we are coming back!
 
This free event offers a unique opportunity to hear from company directors about their latest plans and strategy for their firms' growth and development. You have the opportunity to ask the questions that matter to you and network with fellow investors over drinks and canapés.
Who Should Attend?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Wednesday 15th February 2017

Venue:

Radisson Blu Hotel Edinburgh, 80 High Street, The Royal Mile, Edinburgh, EH11TH

Event Timings:
17.30 
Registration and coffee
17.55 
Presentations
• Alex Borrelli, Chairman & CEO - BMR (BMR)
• Jeremy Hawke, Mining & Operations Director - BMR (BMR)
• Ed Molyneux, CEO - FreeAgent (FREE)
• Michael Hunt, CFO - ReNeuron Group (RENE)
• Richard Clemmey, MD - Tertiary Minerals (TYM)
• Martin Perrin, CFO - Vipera (VIP)
20.45 
Drinks reception and canapés
21.45 
Close
AJ Bell Youinvest
AJ Bell Youinvest 

AJ Bell Youinvest is a multi-award winning provider of SIPPs, stocks and shares ISAs, Junior ISAs, Junior SIPPs and share dealing accounts. We offer customers access to a market leading range of investment options, including: shares, funds, ETFs, investment trusts and much more. Our online dealing service starts from just £4.95 and never costs more than £9.95 per deal.

BMR (BMR)
BMR (BMR) 

BMR has successfully developed a proprietary acid/brine leach process that enables it to achieve high metal recoveries from the different tailings deposits.

BMR Group PLC is listed on AIM under the ticker BMR.

The Company is focused on the recovery of lead and zinc from the tailings deposits of Zambia’s oldest mine at Kabwe.

FreeAgent (FREE)
FreeAgent (FREE) 

FreeAgent launched in 2007, hewn from the frustration that managing company finances was just too damn hard for most small businesses and freelancers. Since then we’ve doggedly stuck to our mantra of demystifying accounting and redefining the relationship people have with their finances.

Ambitious? Sure. Crazy? Quite possibly, but we think it might just work.

We’ve won some important awards over the years, but we’re most proud of the lovely things our users say about us, and the super smart and friendly team we’ve built.

We’re based in the Scottish capital Edinburgh, recently described as “Probably the most beautiful city we have ever seen” by The Black Eyed Peas! High praise indeed.

 

ReNeuron Group (RENE)
ReNeuron Group (RENE) 

ReNeuron is a leading, clinical-stage cell therapy development business.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. 

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.

Tertiary Minerals (TYM)
Tertiary Minerals (TYM) 

Tertiary Minerals plc (ticker symbol 'TYM') is an AIM-traded mineral exploration and development company building a significant strategic position in the fluorspar sector.

Fluorspar is an essential raw material in the chemical, steel and aluminium industries with no large scale commercial alternative, or recycling available. Tertiary controls two significant Scandinavian projects (Storuman in Sweden and Lassedalen in Norway) and a large deposit of strategic significance in Nevada USA (MB Project) from which the Company is planning to produce premium grade fluorspar - acid-spar. 

 

Vipera (VIP)
Vipera (VIP) 

Vipera is a leading provider of mobile financial services platforms. The Vipera platform provides the easiest, fastest, most cost-effective way to develop and operate mobile data services. Solutions powered by Vipera run today on more than 500,000 phones, on hundreds of mobile networks in many countries. Founded in 2005, Vipera has offices in Zurich, Milan and London.

Sponsored by:
AJ Bell Youinvest
Shares

hangon - 27 May 2017 13:30 - 69 of 69

Take ReNeuron [RENE ].... at Exhibition date Oct 2016 sp 2.5pence....now 7 months later it's below 2p (( DYOR )). That looks like the Exh. was unhelpful.....
One might presume that the Co. was unable to stem the rot that whatever it was they do.....no-one thinks they do it very well.
Ten years ago their sp was 26p . . . so they need a very convincing story to get anywhere near that level. Maybe there is a CONsolidation ahead . . . but more-likely the Begging-bowl.
Although I don't Buy this, even at its attractive price . . . . but then, I know nowt about their "risks" - anyone support them?
What story did they give to punters at the Show?
EDIT(4Aug2017)-sp a bit lower. Ann Report DYOR shows losses higher than prev. Cash reserves £53m - that's it.
EDIT (4Dec2017)-1p95 doesn't look like a "recovery" to me.... indeed they appear to have several interesting platforms, but Clinical Trials are in their infancy - so no profits soon, eh?
EDIT (17Jan2018)- CONsolidation notice -DYOR- looks like 100:1 will it make any difference? I doubt it...
EDIT ( 24Jan2018 )_ sp now 137p -( representing a prior CONsolidation=1p37 ). If Management is working hard this may improve, but . . . .
EDIT ( 20June2018)- sp88p ( Up 23% today)- on yet no news...? -or- comments
Register now or login to post to this thread.